Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06599619 | Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi | recruiting | — | 30 | John KirkwoodOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | recruiting | Phase 3 | 632 | mAbxience Research S.L.INDUSTRY | 2 | Jan 21, 2026 |
| clinicaltrials |
| NCT06199713 | Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients | recruiting | — | 24 | University of Wisconsin, MadisonOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07318051 | Sample Collection for Ongoing Research and Product Evaluation Study(SCORE) | recruiting | — | 9,600 | Natera, Inc.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07336979 | Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT03829254 | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | recruiting | Phase 1 / Phase 2 | 135 | NuCana plcOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06887348 | A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3(RPx) | recruiting | — | 50 | Replimune, Inc.INDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07161310 | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors(MitoCancer) | recruiting | N/A | 45 | Goethe UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | recruiting | Phase 2 | 105 | NYU Langone HealthOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05307289 | Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma(MEL-META) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07302607 | Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021(IMM) | recruiting | — | 221 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06994208 | Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.(MELA_2025) | recruiting | — | 25 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07251335 | Melanoma of the Skin and Exposure to Solar Ultraviolet Radiation at Work in Modena Territory: a Case-control Study to Promote an Active Search and Prevention of Occupational Diseases Based on Recent INAIL Criteria(Mesur) | recruiting | — | 300 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03567889 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients(NeoDREAM) | recruiting | Phase 3 | 186 | Philogen S.p.A.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06794775 | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma(SWE-NEO) | recruiting | Phase 3 | 128 | Hildur HelgadottirOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT05098184 | A Study of GC101 TIL in Advanced Melanoma (10hospital) | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07277920 | Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions | recruiting | — | 200 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06194929 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma(DETERMINE) | recruiting | Phase 1 / Phase 2 | 33 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | recruiting | Phase 1 | 6 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies(LONGSAFE) | recruiting | N/A | 40 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07223411 | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | recruiting | — | 20 | John KirkwoodOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06472661 | FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma(Mel 70) | recruiting | Early Phase 1 | 11 | University of VirginiaOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07237100 | Mirdametinib in Patients With Advanced NF1-mutant Melanoma | recruiting | Phase 2 | 10 | Kevin Kim, MDOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05429138 | Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma(MELpreserv) | recruiting | — | 80 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06206707 | FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis(Immunobiome) | recruiting | N/A | 20 | University of AarhusOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | recruiting | Phase 2 | 99 | Emory UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02775643 | Molecular Analysis of Childhood and Adolescent Melanocytic Lesions | recruiting | — | 500 | St. Jude Children's Research HospitalOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT07148245 | Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma | recruiting | — | 300 | University of California, San FranciscoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04513028 | Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma | recruiting | N/A | 30 | Kelly McMastersOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT07215182 | [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer(BEFAST) | recruiting | Phase 2 | 20 | Barbara Malene FischerOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT07206017 | Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous Melanoma.(MELFIB) | recruiting | N/A | 20 | University Medical Center GroningenOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT00722228 | Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT01898039 | Modified Vaccine for High Risk or Low Residual Melanoma Patients | recruiting | Phase 1 / Phase 2 | 50 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04548817 | Neurocutaneous Melanocytosis Registry | recruiting | — | 100 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT01205815 | Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment | recruiting | — | 3,000 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 26, 2026source: clinicaltrials